Amarin Shares Up 5% as FDA Says October 16th Advisory Committee Meeting Will Take Place as Scheduled

Loading...
Loading...
Amarin Corporation plc
AMRN
, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was notified by the U.S. Food and Drug Administration (FDA) that the scheduled advisory committee meeting to be held on October 16, 2013 in connection with the proposed Vascepa® (icosapent ethyl) ANCHOR indication will take place as scheduled despite the current Federal Government lapse in appropriations.
See full press release
Posted In: NewsGuidanceContractsAsset SalesManagementM&AGlobal
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...